Geode Capital Management
TRIL

Geode Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Geode Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-850,207
Closed -$14.9M – 5036
2021
Q3 		$14.9M Buy
850,207
+10,318
+1% +$121K ﹤0.01% 2167
2021
Q2 		$8.15M Buy
839,889
+766,327
+1,042% +$7.21M ﹤0.01% 2604
2021
Q1 		$810K Buy
73,562
+2,105
+3% +$26K ﹤0.01% 3646
2020
Q4 		$1.07M Buy
71,457
+55,795
+356% +$805K ﹤0.01% 3351
2020
Q3 		$222K Sell
15,662
-1,586
-9% -$15.8K ﹤0.01% 3684
2020
Q2 		$139K Hold
17,248
– – ﹤0.01% 3771
2020
Q1 		$69K Sell
17,248
-85,477
-83% -$323K ﹤0.01% 3860
2019
Q4 		$105K Hold
102,725
– – ﹤0.01% 3972
2019
Q3 		$31K Hold
102,725
– – ﹤0.01% 4110
2019
Q2 		$33K Buy
102,725
+76,098
+286% +$39.2K ﹤0.01% 4122
2019
Q1 		$17K Hold
26,627
– – ﹤0.01% 4104
2018
Q4 		$45K Buy
26,627
+16,541
+164% +$49.7K ﹤0.01% 4012
2018
Q3 		$58K Hold
10,086
– – ﹤0.01% 4015
2018
Q2 		$60K Buy
+10,086
New +$64.3K ﹤0.01% 3960

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Geode Capital Management's TRIL Position: Q4 2021 in Review

Geode Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 850,207 shares — an estimated $14.9M sold.

Geode Capital Management first reported a position in TRIL in Q2 2018 and held it in 14 quarters. The position peaked at $14.9M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Geode Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Geode Capital Management sold 850,207 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $14.9M.
  • Geode Capital Management first reported a position in Trillium Therapeutics Inc. in Q2 2018 and held it in 14 quarters.
  • Geode Capital Management's Trillium Therapeutics Inc. position peaked at $14.9M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Geode Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.